https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-data-presentation BiopharmaWatch en 2026-11-07T21:15:00.000Z Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates https://www.biopharmawatch.com/news/JNJ/j-j-icotyde-improves-psoriatic-arthritis-activity BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://www.biopharmawatch.com/news/JNJ/jnj-nipocalimab-phase-2-sjogrens-disease-data BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-alkivia-data-acr-convergence-2026 BiopharmaWatch en 2026-11-07T15:01:00.000Z argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/OGN/real-world-evidence-hadlima-acr-meeting BiopharmaWatch en 2026-11-07T15:00:00.000Z New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System https://www.biopharmawatch.com/news/LFMD/lifemd-reschedules-q3-2026-earnings-call BiopharmaWatch en 2026-11-07T00:25:00.000Z LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026 https://www.biopharmawatch.com/news/BFRI/biofrontera-third-quarter-2026-results BiopharmaWatch en 2026-11-06T23:08:00.000Z Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 https://www.biopharmawatch.com/news/ANGO/angiodynamics-inducement-grants-ceo-appointment BiopharmaWatch en 2026-11-06T23:00:00.000Z AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-q3-2026-results BiopharmaWatch en 2026-11-06T22:40:00.000Z bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization https://www.biopharmawatch.com/news/SRZN/surrozen-present-upcoming-healthcare-investor-conference-20261106 BiopharmaWatch en 2026-11-06T21:40:00.000Z Surrozen to Present at Upcoming Healthcare Investor Conference https://www.biopharmawatch.com/news/SNWV/sanuwave-conference-call-q3-2026-results BiopharmaWatch en 2026-11-06T21:30:00.000Z Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-06T21:30:00.000Z Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:30:00.000Z ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/JAGX/jaguar-health-special-meeting-approval-2026 BiopharmaWatch en 2026-11-06T21:15:00.000Z Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders https://www.biopharmawatch.com/news/ENTX/entera-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-06T21:15:00.000Z Entera Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/CDNA/caredx-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KARD/kardigan-phase-2b-katalyst-av-trial-enrollment-complete BiopharmaWatch en 2026-11-06T21:05:00.000Z Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-11-06T21:05:00.000Z Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-inducement-awards-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z Spyre Therapeutics Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/ICCC/immucell-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-06T21:05:00.000Z ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-merger-mentari-therapeutics BiopharmaWatch en 2026-11-06T21:05:00.000Z InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z LeMaitre to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NTLA/intellia-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-11-06T21:05:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-conference-call-vrdn-008-phase-1-data BiopharmaWatch en 2026-11-06T21:01:00.000Z Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-webcast-nkx019-acr-convergence-2026 BiopharmaWatch en 2026-11-06T21:01:00.000Z Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:01:00.000Z BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:01:00.000Z NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INAB/in8bio-stock-option-inducement-grant BiopharmaWatch en 2026-11-06T21:01:00.000Z IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FTH/faeth-report-pik-201-phase-2-data-event-november-9-2026 BiopharmaWatch en 2026-11-06T21:00:00.000Z Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026 https://www.biopharmawatch.com/news/IMNM/immunome-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261106 BiopharmaWatch en 2026-11-06T21:00:00.000Z Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BMY/bmy-phase-3-data-camzyos-pediatric-ohcm BiopharmaWatch en 2026-11-06T21:00:00.000Z Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:00:00.000Z Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BRVE/braveheart-bio-hengrui-pharma-hrs-bhb-1893-data BiopharmaWatch en 2026-11-06T20:15:00.000Z Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-investor-events-participation BiopharmaWatch en 2026-11-06T20:00:00.000Z Alpha Cognition to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/ALGN/align-technology-extel-2026-rankings BiopharmaWatch en 2026-11-06T17:59:00.000Z Align Technology Recognized in Extel’s 2026 All-America Executive Team Rankings https://www.biopharmawatch.com/news/GILD/lenacapavir-hiv-prevention-trial-results BiopharmaWatch en 2026-11-06T17:16:00.000Z New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-phase-1-2a-study-melanoma BiopharmaWatch en 2026-11-06T17:00:00.000Z Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-2-trial-brenetafusp-kimmtrak BiopharmaWatch en 2026-11-06T17:00:00.000Z Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma https://www.biopharmawatch.com/news/CHE/chemed-quarterly-dividend-announcement BiopharmaWatch en 2026-11-06T16:23:00.000Z Chemed Corporation Declares Quarterly Dividend of 70 Cents https://www.biopharmawatch.com/news/HCWB/hcw-biologics-hcw11-040-sitc-presentation BiopharmaWatch en 2026-11-06T16:00:00.000Z HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer https://www.biopharmawatch.com/news/EVAX/evax-01-phase-2-trial-results BiopharmaWatch en 2026-11-06T16:00:00.000Z New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/INCY/2026-ingenuity-awards-gvhd-recipients BiopharmaWatch en 2026-11-06T15:40:00.000Z 2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute https://www.biopharmawatch.com/news/OSRH/osr-health-exercises-15-million-vxm01-equity-option BiopharmaWatch en 2026-11-06T15:11:00.000Z OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes https://www.biopharmawatch.com/news/HALO/halozyme-reaffirms-projects-zero-minimal-impact-royalty-revenue-through-least BiopharmaWatch en 2026-11-06T15:04:00.000Z Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 https://www.biopharmawatch.com/news/QGEN/qiagen-shareholders-approve-jonathan-pratt BiopharmaWatch en 2026-11-06T15:00:00.000Z QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director https://www.biopharmawatch.com/news/HALO/fda-approves-rybrevant-faspro-halozyme-advanced-cancer BiopharmaWatch en 2026-11-06T14:57:00.000Z U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/INKT/mink-therapeutics-sitc-2026-data-inkt-therapy BiopharmaWatch en 2026-11-06T14:48:00.000Z MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) https://www.biopharmawatch.com/news/IRTC/irhythm-holdings-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-06T14:15:00.000Z iRhythm Holdings to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HCWB/hcw-biologics-t-cell-engager-sitc-2026 BiopharmaWatch en 2026-11-06T14:15:00.000Z HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting https://www.biopharmawatch.com/news/ALGN/align-technology-270-million-stock-repurchase BiopharmaWatch en 2026-11-06T14:10:00.000Z Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-sitc-presentation-2026 BiopharmaWatch en 2026-11-06T14:05:00.000Z Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) https://www.biopharmawatch.com/news/OBX/obsidian-therapeutics-amsoki-cel-sitc-2026 BiopharmaWatch en 2026-11-06T14:05:00.000Z Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMRX/atebimetinib-combinations-ratios-cancer-models-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:37.000Z Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-treatment-survival-mcrc-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2026-data BiopharmaWatch en 2026-11-06T14:00:00.000Z Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-ctx-10726-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMCR/immunocore-q3-2026-financial-results-update BiopharmaWatch en 2026-11-06T14:00:00.000Z Immunocore reports third quarter financial results and provides a business update https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q3-2026-results BiopharmaWatch en 2026-11-06T14:00:00.000Z Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/BCTX/briacell-bria-pro-positive-preclinical-data-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 https://www.biopharmawatch.com/news/IMNN/imnn-001-activates-t-cell-immunity-advanced-ovarian-cancer BiopharmaWatch en 2026-11-06T14:00:00.000Z IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-q3-2026-revenue-outlook BiopharmaWatch en 2026-11-06T13:30:00.000Z OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook https://www.biopharmawatch.com/news/BCDA/biocardia-completes-pmda-consultation-cardiamp-approval BiopharmaWatch en 2026-11-06T13:30:00.000Z BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video BiopharmaWatch en 2026-11-06T13:30:00.000Z Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-06T13:30:00.000Z CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 https://www.biopharmawatch.com/news/ICUI/icu-medical-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-06T13:30:00.000Z ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-q3-2026-results BiopharmaWatch en 2026-11-06T13:15:00.000Z CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ACRV/acrivon-expands-immunology-inflammation-acquisition-phase-2-ready-differentiated-oral BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ACRV/acrivon-acquires-acr-525-jak1-inhibitor BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ASND/transcon-cnp-market-exclusivity-eu-approval BiopharmaWatch en 2026-11-06T13:00:00.000Z Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z enGene to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-nasdaq-listing-rule-5635-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDXG/mimedx-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z MIMEDX to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-business-progress-q3-2026 BiopharmaWatch en 2026-11-06T13:00:00.000Z Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-06T13:00:00.000Z Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/IART/integra-lifesciences-2026-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-06T13:00:00.000Z Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference https://www.biopharmawatch.com/news/NHC/nhc-reports-third-quarter-2026-earnings BiopharmaWatch en 2026-11-06T12:30:00.000Z NHC Reports Third Quarter 2026 Earnings https://www.biopharmawatch.com/news/SNGX/soligenix-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:30:00.000Z Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EHC/encompass-health-sea-pines-hospital-closure BiopharmaWatch en 2026-11-06T12:30:00.000Z Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-surgeon-guided-autonomy-intelligent-surgery BiopharmaWatch en 2026-11-06T12:30:00.000Z Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery https://www.biopharmawatch.com/news/DAVI/davion-healthcare-appoints-vienna-capital-partners BiopharmaWatch en 2026-11-06T12:30:00.000Z Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy https://www.biopharmawatch.com/news/IFRX/inflarx-phase-1-data-izicopan-safety-profile BiopharmaWatch en 2026-11-06T12:30:00.000Z InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:30:00.000Z Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CANF/can-fite-pursue-global-licensing-strategic-partnerships-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/CANF/can-fite-global-licensing-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/NEO/neogenomics-participate-investor-conferences BiopharmaWatch en 2026-11-06T12:05:00.000Z NeoGenomics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HLF/herbalife-participate-stephens-investment-conference BiopharmaWatch en 2026-11-06T12:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19 https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Anika Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q3-2026-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Treace Medical Concepts Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-tailorplasty-surgical-cases BiopharmaWatch en 2026-11-06T12:04:00.000Z Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System https://www.biopharmawatch.com/news/CGC/canopy-growth-q2-fy2027-financial-results BiopharmaWatch en 2026-11-06T12:03:08.000Z Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-precise-btn-results-ata-meeting BiopharmaWatch en 2026-11-06T12:00:00.000Z Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting https://www.biopharmawatch.com/news/BHC/bausch-health-salix-liver-meeting-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences-scientific-meetings BiopharmaWatch en 2026-11-06T12:00:00.000Z EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KRRO/korro-presents-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Korro to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2026-financial-results BiopharmaWatch en 2026-11-06T12:00:00.000Z Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 https://www.biopharmawatch.com/news/MSLE/satellos-changes-efficacy-endpoint-basecamp-trial BiopharmaWatch en 2026-11-06T12:00:00.000Z Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback https://www.biopharmawatch.com/news/LLY/lilly-hims-hers-expand-access-fda-approved-medicines BiopharmaWatch en 2026-11-06T11:47:00.000Z Lilly and Hims & Hers expand access to FDA-approved Lilly medicines https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-q3-fiscal-2026-results BiopharmaWatch en 2026-11-06T11:45:27.000Z AirSculpt Technologies Reports Third Quarter Fiscal 2026 Results https://www.biopharmawatch.com/news/MRNA/moderna-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-06T11:45:00.000Z Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/BKD/brookdale-announces-third-quarter-2026-results BiopharmaWatch en 2026-11-06T11:30:00.000Z Brookdale Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/VOGX/vogenx-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-06T11:30:00.000Z Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q3-2026-results BiopharmaWatch en 2026-11-06T11:27:00.000Z Elanco Animal Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ELAN/elanco-pet-health-consumer-research-october-2026 BiopharmaWatch en 2026-11-06T11:27:00.000Z October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-06T10:50:00.000Z Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/RARE/ultragenyx-maa-ux111-review-mhra BiopharmaWatch en 2026-11-06T08:30:00.000Z Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) https://www.biopharmawatch.com/news/MOLN/molecular-partners-preclinical-data-mp0632-sitc-2026 BiopharmaWatch en 2026-11-06T06:00:08.000Z Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 https://www.biopharmawatch.com/news/PHAR/mhra-approves-pharming-joenja-treatment-children-apds BiopharmaWatch en 2026-11-06T06:00:00.000Z MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. https://www.biopharmawatch.com/news/INO/inovio-pricing-75-million-public-offering BiopharmaWatch en 2026-11-06T04:18:00.000Z INOVIO Announces Pricing of Approximately $75 Million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-public-offering-pricing BiopharmaWatch en 2026-11-06T03:42:00.000Z Orchestra BioMed Announces Pricing of Public Offering https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-head-neck-cancer BiopharmaWatch en 2026-11-06T02:03:00.000Z Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-bamzireotide-trial-data-nanets-2026 BiopharmaWatch en 2026-11-06T01:10:00.000Z Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend-20261106 BiopharmaWatch en 2026-11-06T01:00:00.000Z NHC Announces Common Dividend